Graft versus tumor effect in the brain of a child with recurrent metastatic medulloblastoma

Hisham Abdel-Azim, Neena Kapoor, Kris M. Mahadeo, Jonathan L. Finlay

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Marrow ablative chemotherapy (MAC) with autologous hematopoietic stem cell transplantation (HSCT) is limited by poor bone marrow reserve after chemotherapy and/or radiotherapy, and the extent of bone/bone marrow disease. We report a child with recurrent metastatic medulloblastoma who received an allogeneic HSCT while in relapse and subsequently achieved radiological resolution of disease and favorable marrow minimal residual disease (MRD) response. Disease recurred intra-cranially at 304 days post-HSCT. Tumor biopsy 488 days post-HSCT showed infiltration with donor lymphocytes demonstrating graft-versus-tumor (GVT) effect. The patient remained alive >2 years post-HSCT. Allogeneic HSCT may be a consideration for high-risk recurrent medulloblastoma.

Original languageEnglish (US)
Pages (from-to)1667-1669
Number of pages3
JournalPediatric Blood and Cancer
Volume62
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Medulloblastoma
Hematopoietic Stem Cell Transplantation
Transplants
Brain
Neoplasms
Bone Marrow
Bone Marrow Diseases
Drug Therapy
Residual Neoplasm
Radiotherapy
Tissue Donors
Lymphocytes
Biopsy
Bone and Bones
Recurrence

Keywords

  • Allogeneic stem cell transplantation
  • Graft versus tumor effect in brain
  • Medulloblastoma

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Graft versus tumor effect in the brain of a child with recurrent metastatic medulloblastoma. / Abdel-Azim, Hisham; Kapoor, Neena; Mahadeo, Kris M.; Finlay, Jonathan L.

In: Pediatric Blood and Cancer, Vol. 62, No. 9, 01.09.2015, p. 1667-1669.

Research output: Contribution to journalArticle

Abdel-Azim, Hisham ; Kapoor, Neena ; Mahadeo, Kris M. ; Finlay, Jonathan L. / Graft versus tumor effect in the brain of a child with recurrent metastatic medulloblastoma. In: Pediatric Blood and Cancer. 2015 ; Vol. 62, No. 9. pp. 1667-1669.
@article{4c64871329564968839919a043f3357c,
title = "Graft versus tumor effect in the brain of a child with recurrent metastatic medulloblastoma",
abstract = "Marrow ablative chemotherapy (MAC) with autologous hematopoietic stem cell transplantation (HSCT) is limited by poor bone marrow reserve after chemotherapy and/or radiotherapy, and the extent of bone/bone marrow disease. We report a child with recurrent metastatic medulloblastoma who received an allogeneic HSCT while in relapse and subsequently achieved radiological resolution of disease and favorable marrow minimal residual disease (MRD) response. Disease recurred intra-cranially at 304 days post-HSCT. Tumor biopsy 488 days post-HSCT showed infiltration with donor lymphocytes demonstrating graft-versus-tumor (GVT) effect. The patient remained alive >2 years post-HSCT. Allogeneic HSCT may be a consideration for high-risk recurrent medulloblastoma.",
keywords = "Allogeneic stem cell transplantation, Graft versus tumor effect in brain, Medulloblastoma",
author = "Hisham Abdel-Azim and Neena Kapoor and Mahadeo, {Kris M.} and Finlay, {Jonathan L.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/pbc.25525",
language = "English (US)",
volume = "62",
pages = "1667--1669",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Graft versus tumor effect in the brain of a child with recurrent metastatic medulloblastoma

AU - Abdel-Azim, Hisham

AU - Kapoor, Neena

AU - Mahadeo, Kris M.

AU - Finlay, Jonathan L.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Marrow ablative chemotherapy (MAC) with autologous hematopoietic stem cell transplantation (HSCT) is limited by poor bone marrow reserve after chemotherapy and/or radiotherapy, and the extent of bone/bone marrow disease. We report a child with recurrent metastatic medulloblastoma who received an allogeneic HSCT while in relapse and subsequently achieved radiological resolution of disease and favorable marrow minimal residual disease (MRD) response. Disease recurred intra-cranially at 304 days post-HSCT. Tumor biopsy 488 days post-HSCT showed infiltration with donor lymphocytes demonstrating graft-versus-tumor (GVT) effect. The patient remained alive >2 years post-HSCT. Allogeneic HSCT may be a consideration for high-risk recurrent medulloblastoma.

AB - Marrow ablative chemotherapy (MAC) with autologous hematopoietic stem cell transplantation (HSCT) is limited by poor bone marrow reserve after chemotherapy and/or radiotherapy, and the extent of bone/bone marrow disease. We report a child with recurrent metastatic medulloblastoma who received an allogeneic HSCT while in relapse and subsequently achieved radiological resolution of disease and favorable marrow minimal residual disease (MRD) response. Disease recurred intra-cranially at 304 days post-HSCT. Tumor biopsy 488 days post-HSCT showed infiltration with donor lymphocytes demonstrating graft-versus-tumor (GVT) effect. The patient remained alive >2 years post-HSCT. Allogeneic HSCT may be a consideration for high-risk recurrent medulloblastoma.

KW - Allogeneic stem cell transplantation

KW - Graft versus tumor effect in brain

KW - Medulloblastoma

UR - http://www.scopus.com/inward/record.url?scp=84938206213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938206213&partnerID=8YFLogxK

U2 - 10.1002/pbc.25525

DO - 10.1002/pbc.25525

M3 - Article

C2 - 25894457

AN - SCOPUS:84938206213

VL - 62

SP - 1667

EP - 1669

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 9

ER -